Figure 3.
Effect of TCZ over time on (A) mean HAQ-DI, (B) achievement of HAQ-DI ≤0.5, and (C) achievement of HAQ-DI ≤0.5 by disease duration subgroups. DAS28-ESR, Disease Activity Score based on 28-joint-erythrocyte sedimentation rate; TCZ, tocilizumab.

Effect of TCZ over time on (A) mean HAQ-DI, (B) achievement of HAQ-DI ≤0.5, and (C) achievement of HAQ-DI ≤0.5 by disease duration subgroups. DAS28-ESR, Disease Activity Score based on 28-joint-erythrocyte sedimentation rate; TCZ, tocilizumab.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close